Table 2.
Distribution of drug classes used by ARISTOTLE trial participants, by number of concomitant drugs used
| Drug class | No of drugs | P | ||
|---|---|---|---|---|
| 0-5 (n=6943) | 6-8 (n=6502) | ≥9 (n=4756) | ||
| Alimentary tract and metabolism | 962 (13.9) | 3045 (46.8) | 4094 (86.1) | <0.001 |
| Blood and blood forming organs (excluding apixaban/warfarin) | 2282 (32.9) | 4322 (66.5) | 4116 (86.5) | <0.001 |
| Cardiovascular system | 6460 (93.0) | 6468 (99.5) | 4737 (99.6) | <0.001 |
| Dermatological drugs | 34 (0.5) | 96 (1.5) | 346 (7.3) | <0.001 |
| Genitourinary system and sex hormones | 173 (2.5) | 510 (7.8) | 936 (19.7) | <0.001 |
| Systemic hormonal preparations, excluding sex hormones and insulins | 181 (2.6) | 508 (7.8) | 852 (17.9) | <0.001 |
| Anti-infective drugs for systemic use | 44 (0.6) | 161 (2.5) | 347 (7.3) | <0.001 |
| Antineoplastic and immunomodulating agents | 14 (0.2) | 60 (0.9) | 152 (3.2) | <0.001 |
| Musculoskeletal system | 202 (2.9) | 688 (10.6) | 1350 (28.4) | <0.001 |
| Nervous system | 523 (7.5) | 1448 (22.3) | 2376 (50.0) | <0.001 |
| Antiparasitic products, insecticides, and repellents | 0 (0.0) | 13 (0.2) | 46 (1.0) | <0.001 |
| Respiratory system | 164 (2.4) | 600 (9.2) | 1336 (28.1) | <0.001 |
| Sensory organs | 41 (0.6) | 115 (1.8) | 300 (6.3) | <0.001 |
| Various | 126 (1.8) | 247 (3.8) | 630 (13.2) | <0.001 |
| Interacting drugs | ||||
| ≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inhibitor | 1128 (16.2) | 1431 (22.0) | 1301 (27.4) | <0.001 |
| ≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inducer | 12 (0.2) | 34 (0.5) | 47 (1.0) | <0.001 |
| ≥1 highly probable VKA inhibiting drug | 8 (0.1) | 19 (0.3) | 33 (0.7) | <0.001 |
| ≥1 highly probable VKA potentiating drug | 973 (14.0) | 1406 (21.6) | 1387 (29.2) | <0.001 |
| Use of acetylsalicylic acid, NSAIDs, or prednisone | 956 (13.8) | 2064 (31.7) | 2362 (49.7) | <0.001 |
Data are no (%) of patients. CYP=cytochrome P450; VKA=vitamin K antagonist, NSAIDs=non-steroidal anti-inflammatory drugs.